Abstract
The exquisite specificity of antibodies can be harnessed to effect targeted degradation of membrane proteins. Here, we demonstrate targeted protein removal utilising a protein degradation domain derived from the endogenous human protein Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9). Recombinant antibodies genetically fused to this domain drive the degradation of membrane proteins that undergo constitutive internalisation and recycling, including the transferrin receptor and the human cytomegalovirus latency-associated protein US28. We term this approach PACTAC (PCSK9-Antibody Clearance-Targeting Chimeras).
Funding Information
  • Wellcome Trust (WT 207455/Z/17/Z)
  • Wellcome Trust (098406/Z/12/B)
  • Medical Research Council (MR/S00081X/1)
  • Deutsches Zentrum für Infektionsforschung (DZIF MD TI 07.003)
  • CIMR Flow Cytometry Core Facility
  • Cambridge NIHR BRC Cell Phenotyping Hub

This publication has 64 references indexed in Scilit: